Complement inhibition in severe COVID-19 – Blocking C5a seems to be key: Author's reply
Author:
Funder
Alexion Pharmaceuticals
Publisher
Elsevier BV
Subject
General Medicine
Reference5 articles.
1. Complement inhibition in severe COVID-19 – blocking C5a seems to be key;Lim;EClinicalMedicine,2021
2. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study;Annane;EClinicalMedicine,2020
3. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation;Harder;Blood,2017
4. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial;Vlaar;Lancet Rheumatol,2020
5. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis;Carvelli;Nature,2020
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting C5a is beneficial in critically ill COVID-19 patients;Immunobiology;2023-11
2. Inhibiting C5 in patients with severe COVID-19—the incorrect target?;The Lancet Respiratory Medicine;2023-09
3. Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients;Intensive Care Medicine Experimental;2023-06-19
4. C5 inhibitors are not C5a inhibitors;Expert Review of Anti-infective Therapy;2023-03-31
5. Complement activation in COVID-19 and targeted therapeutic options: A scoping review;Blood Reviews;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3